This Note examines how artificial intelligence (“AI”) is fundamentally transforming pharmaceutical research and development (“R&D”), altering the cost, risk, and timelines that traditionally justify regulatory exclusivity protections. As AI-enabled technologies accelerate drug discovery and increase clinical success rates, the traditional assumptions supporting lengthy exclusivity periods are becoming less persuasive. This Note contends that Congress should […]